FI107704B - Förfarande för framställning av en farmaceutisk blandning, som innehåller en fysiologiskt aktiv polypeptid och ett absorbering befrämjande ämne - Google Patents

Förfarande för framställning av en farmaceutisk blandning, som innehåller en fysiologiskt aktiv polypeptid och ett absorbering befrämjande ämne Download PDF

Info

Publication number
FI107704B
FI107704B FI922579A FI922579A FI107704B FI 107704 B FI107704 B FI 107704B FI 922579 A FI922579 A FI 922579A FI 922579 A FI922579 A FI 922579A FI 107704 B FI107704 B FI 107704B
Authority
FI
Finland
Prior art keywords
acid
sucrose
mixture
weight
fatty acid
Prior art date
Application number
FI922579A
Other languages
English (en)
Finnish (fi)
Other versions
FI922579A0 (fi
FI922579A (fi
Inventor
Yukiko Inamoto
Shigeyuki Takama
Takahiko Wato
Akiya Yamada
Naoki Uchida
Misuzu Kadoriku
Original Assignee
Teikoku Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Seiyaku Kk filed Critical Teikoku Seiyaku Kk
Publication of FI922579A0 publication Critical patent/FI922579A0/fi
Publication of FI922579A publication Critical patent/FI922579A/fi
Application granted granted Critical
Publication of FI107704B publication Critical patent/FI107704B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Claims (3)

  1. 24 107704
  2. 1. Förfarande för framställning av en farmaceutisk blandning, som innehäller 5 en fysiologiskt aktiv polypeptid och ett absorbering befrämjande ämne, som be-star av en blandning av en organisk syra en fettsyrasackarosester, vilken ester är beständig mot sönderfall förorsakad av proteasverksamhet, kännetecknat därav, att den aktiva polypeptiden, det absorbering befrämjande ämnet, en far-maceutiskt godtagbar bärare eller ett utspädningsämne blandas sinsemellan 10 och av blandningen bildas en sedvanlig farmaceutiskt prepartform, där den fysiologiskt aktiva polypeptiden är vald urgruppen insulin, angiotensin, vasopressin, desmopressin, LH-RH (gulkroppshormon frigörande hormon), somatostatin, kalcitonin, glukagon, oxytocin, gastrinit, somatomedinit, sekretin, h-ANP (human natriuretpeptid), ACTH (adrenokortikotropisk hormon), MSH (melano-15 cyter stimulerande hormon), β-endorfin, muramyldipeptid, enkefalinit, neurotensin, bombesin, VIP (vasoaktiv intetinal peptid), CCK-8 (kolekystokin-8), PTH (paratyroidhormon), CGRP (till kalcitoningen anslutande peptid), TRH (tyrotro-pin frigörande hormon), endotelin, TSH (sköldkörteln stimulerande hormon), och deras derivat, vilken organisk syra är vald ur gruppen ättiksyra, smörsyra, [/ ’ 20 fumarsyra, malonsyra, ftalsyra, propionsyra, glutarsyra, adipinsyra, valeriansy- • · • / ra, kaproinsyra, maleinsyra, askorbinsyra, isoaskorbinsyra, äppelsyra, ·/ | bärnstenssyra, mjölksyra, vinsyra, citronsyra och bensoesyra, och deras farma- *· ceutiskt godtagbara salter, och vilken fettsyrasackarosester är vald ur gruppen • · > *;/: sackarosstearat, sackarospalmitat, sackarosoleat, sackaroslaurat, sackarosbe- 25 henat och sackaroserukat, och dears kombiantioner, vilken organisk syra är närvarande 0,1 - 70 vikt-% av hela blandningens vikt [,/ och fettsyrasackarosestern är närvarande 0,1 - 50 vikt-% av hela blandningens • · vikt da blandning har formen av ett oralt preparat, eller • · ': den organiska syran är närvarande 0,1 - 30 vikt-% av hela blandningens vikt • » « 30 och fettsyrasackarosestern är närvarande 0,1 - 20 vikt-% av hela blandningens t vikt da blandning har formen av ett sublingualt preparat, eller » · 4 • * · » · » • » • · 25 107704 den organiska syra är närvarande 30 - 90 vikt-% av hela blandningens vikt och fettsyrasackarosestern är närvarande 5-50 vikt-% av hela blandningens vikt da blandning har formen av ett snabblösligt preparat. 5 2. Förfarande enligt patentkravet 1, kännetecknat därav, att den organiska syran är vinsyra, citronsyra, äppelsyra, mjölksyra, bensoesyra eller bärnstens-syra.
  3. 3. Förfarande enligt patentkravet 1, kännetecknat därav, att fettsyrasackaros-10 estern är sackarosstearat, sackarospalmitat, sackarosoleat eller sackaroslau-rat. • · · • 1 • · « • · • · • »1 • · * · « • · · • · · · • · • I I • « • · • ·« t » • · Φ • · · t I 1 • · · « • · • · ·1» • · · • · • · · » • » 1 • · • « • · 1 • · • · • · · • ·
FI922579A 1991-06-07 1992-06-04 Förfarande för framställning av en farmaceutisk blandning, som innehåller en fysiologiskt aktiv polypeptid och ett absorbering befrämjande ämne FI107704B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13646291 1991-06-07
JP13646291 1991-06-07

Publications (3)

Publication Number Publication Date
FI922579A0 FI922579A0 (fi) 1992-06-04
FI922579A FI922579A (fi) 1992-12-08
FI107704B true FI107704B (sv) 2001-09-28

Family

ID=15175681

Family Applications (1)

Application Number Title Priority Date Filing Date
FI922579A FI107704B (sv) 1991-06-07 1992-06-04 Förfarande för framställning av en farmaceutisk blandning, som innehåller en fysiologiskt aktiv polypeptid och ett absorbering befrämjande ämne

Country Status (10)

Country Link
US (1) US5929027A (sv)
EP (1) EP0517211B1 (sv)
AT (1) ATE276767T1 (sv)
AU (1) AU653026B2 (sv)
CA (1) CA2070061C (sv)
DE (1) DE69233413T2 (sv)
ES (1) ES2229203T3 (sv)
FI (1) FI107704B (sv)
NO (1) NO307772B1 (sv)
SG (1) SG43858A1 (sv)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US20010003001A1 (en) 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6610329B2 (en) 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
JP3628713B2 (ja) * 1993-06-07 2005-03-16 帝國製薬株式会社 生理学的に活性なペプチドを含有する膣投与製剤
WO1997036480A1 (en) 1996-03-29 1997-10-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
FR2735131B1 (fr) * 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
EP0904065A4 (en) 1996-06-14 2000-06-14 Emisphere Tech Inc MICRO-ENCLOSED FRAGRANCES AND PRODUCTION METHOD
EP0886471A4 (en) 1996-11-18 2002-07-17 Emisphere Tech Inc METHODS AND COMPOSITIONS FOR INDUCING ORAL TOLERANCE IN MUZZLES
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU726940B2 (en) * 1997-04-14 2000-11-23 Mitsubishi-Tokyo Pharmaceuticals, Inc. Permucosal preparation
EP0880969A1 (en) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
WO2000005261A1 (en) * 1998-07-21 2000-02-03 Monsanto Company Clarification of protein precipitate suspensions using anionic polymeric flocculants
IL140710A0 (en) 1998-07-27 2002-02-10 Emisphere Tech Inc Pulmonary delivery of active agents
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
EP1102742B1 (en) 1998-08-07 2006-06-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU1031500A (en) * 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1154761B1 (en) * 1999-02-22 2008-02-20 Merrion Research I Limited Solid oral dosage form containing an enhancer
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
WO2001000654A2 (en) * 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
DE60038183T2 (de) 1999-12-16 2009-02-19 Emisphere Technologies, Inc. Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
AT409081B (de) * 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
EP1392272B1 (en) 2001-05-11 2014-08-06 Merrion Research III Limited Permeation enhancers
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
CA2484724C (en) * 2002-05-07 2007-01-16 Ferring B.V. Pharmaceutical formulations
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
GB0221712D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods of treatment
EP1572244A1 (en) * 2002-12-11 2005-09-14 Chong Kun Dang Pharmaceutical Corp. Oral formulations for poorly absorptive hydrophilic drugs
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
BRPI0302736B8 (pt) * 2003-06-02 2021-05-25 Ems S/A composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
ATE324869T1 (de) 2003-11-13 2006-06-15 Ferring Bv Blisterverpackung und feste dosierungsform enthaltend desmopressin
EP1708738B1 (en) * 2004-01-12 2016-05-04 MannKind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
JP4601627B2 (ja) * 2004-01-16 2010-12-22 バイオデル， インコーポレイテッド 舌下薬物送達デバイス
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
WO2005089722A1 (en) * 2004-03-12 2005-09-29 Biodel, Inc. Rapid acting drug delivery compositions
WO2006023849A2 (en) 2004-08-20 2006-03-02 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK2314298T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Microparticles comprising diketopiperazinsalte for drug delivery
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
ES2701648T3 (es) * 2005-08-26 2019-02-25 Abbvie Inc Análogos de alfa-MSH terapéuticamente activos
HUE028691T2 (en) 2005-09-14 2016-12-28 Mannkind Corp A method for formulating a drug based on increasing the affinity of crystalline microparticle surfaces towards active ingredients
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
US8039431B2 (en) 2006-02-22 2011-10-18 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
EP2007397B1 (en) 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
AU2007238114B2 (en) * 2006-04-12 2010-10-14 Biodel, Inc. Rapid acting and long acting insulin combination formulations
US8377863B2 (en) * 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
ES2319054B1 (es) 2007-08-06 2010-02-12 Gp Pharm S.A. Composicion farmaceutica oral de desmopresina.
WO2011163272A1 (en) 2010-06-21 2011-12-29 Mannkind Corporation Dry powder drug delivery system and methods
JP5352596B2 (ja) * 2008-01-04 2013-11-27 バイオデル， インコーポレイテッド 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
CN107096012A (zh) 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
PT2296686E (pt) 2008-05-21 2014-05-23 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono não perturbado por noctúria
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
CN109568740B (zh) 2008-06-13 2022-05-27 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
BRPI0914308B8 (pt) 2008-06-20 2021-06-22 Mannkind Corp sistema de inalação
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
WO2010033726A2 (en) 2008-09-17 2010-03-25 The Brigham And Women's Hospital, Inc. Drug delivery composition comprising a self-assembled gelator
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2405963B1 (en) 2009-03-11 2013-11-06 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
JP6073678B2 (ja) 2009-06-18 2017-02-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安全なデスモプレシン投与
EP2496295A1 (en) 2009-11-03 2012-09-12 MannKind Corporation An apparatus and method for simulating inhalation efforts
CA2784120A1 (en) 2009-12-16 2011-07-14 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
BR112013008697A2 (pt) 2010-09-24 2016-06-21 Massachusetts Inst Technology géis nanoestruturados capazes de liberação controlada de agentes encapsulados
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
EP2694402B1 (en) 2011-04-01 2017-03-22 MannKind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
DK2915525T3 (en) 2011-09-19 2021-08-23 Orexo Ab Sublingual abuse-resistant tablets comprising buprenorphine and naloxone
CA2852536A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2014012069A2 (en) 2012-07-12 2014-01-16 Mannkind Corporation Dry powder drug delivery systems and methods
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
EA034393B1 (ru) 2012-11-13 2020-02-03 Адосиа Состав инсулина быстрого действия, содержащий замещенное анионное соединение
KR102246914B1 (ko) 2013-03-15 2021-04-30 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2973099C (en) 2015-01-12 2021-09-14 Enteris Biopharma, Inc. Solid oral dosage forms
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
AU2016335846B2 (en) 2015-10-08 2019-04-04 The Brigham And Women's Hospital, Inc. Stabilized assembled nanostructures for delivery of encapsulated agents
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
CN109310775B (zh) * 2016-05-06 2022-11-18 布里格姆及妇女医院股份有限公司 用于向软骨中受控递送被囊封的药剂的二元自组装凝胶
KR20190038610A (ko) 2016-08-05 2019-04-08 타우루스 디벨롭먼트 컴퍼니 엘엘씨 실온 안정성 경구 칼시토닌 제제
US11020410B2 (en) 2017-02-03 2021-06-01 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
AU2018266131B2 (en) 2017-05-08 2021-07-29 Alivio Therapeutics, Inc. Formulation of nanostructured gels for increased agent loading and adhesion
WO2019102310A1 (en) * 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions
AU2019357859A1 (en) 2018-10-11 2021-06-03 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211769A (en) * 1977-08-24 1980-07-08 Takeda Chemical Industries, Ltd. Preparations for vaginal administration
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
JPS57128634A (en) * 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
JPH01139528A (ja) * 1987-11-24 1989-06-01 Showa Denko Kk 抗潰瘍剤
US5350741A (en) * 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5204327A (en) * 1988-11-18 1993-04-20 Ashi Kasei Kogyo Kabushiki Kaisha Treatment of cerebral edema with anp pharmaceutical compositions
EP0585355B1 (en) * 1991-05-20 1995-03-22 Marion Laboratories, Inc. Multi-layered controlled release formulation
IL99666A (en) * 1991-10-07 1996-09-12 Yeda Res & Dev Vanadyl complexes of hydroxamate chelators and pharmaceutical compositions comprising them
US5482706A (en) * 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition

Also Published As

Publication number Publication date
EP0517211B1 (en) 2004-09-22
FI922579A0 (fi) 1992-06-04
AU653026B2 (en) 1994-09-15
DE69233413T2 (de) 2006-02-02
ATE276767T1 (de) 2004-10-15
SG43858A1 (en) 1997-11-14
CA2070061A1 (en) 1992-12-08
US5929027A (en) 1999-07-27
DE69233413D1 (de) 2004-10-28
NO922232L (no) 1992-12-08
ES2229203T3 (es) 2005-04-16
NO922232D0 (no) 1992-06-05
AU1726492A (en) 1992-12-10
NO307772B1 (no) 2000-05-29
EP0517211A1 (en) 1992-12-09
FI922579A (fi) 1992-12-08
CA2070061C (en) 2004-02-10

Similar Documents

Publication Publication Date Title
FI107704B (sv) Förfarande för framställning av en farmaceutisk blandning, som innehåller en fysiologiskt aktiv polypeptid och ett absorbering befrämjande ämne
RU2198677C2 (ru) Фармацевтическая композиция для пероральной доставки физиологически активного пептидного агента и способ усиления его биодоступности
RU2327484C2 (ru) Фармацевтическая композиция для назального всасывания
KR101191322B1 (ko) 증진제를 함유하는 고형 경구용 투여 제형
JP2911496B2 (ja) 生理活性ポリペプチド含有高吸収性経膣剤
US8119159B2 (en) Solid oral dosage form containing an enhancer
EP0387352B1 (en) Enteric formulations of physiologically active peptides and proteins
US20240041983A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
EP0462071B1 (en) Pharmaceutical resorption-improved somatostatin compositions, their preparation and use
JP3253127B2 (ja) 生理活性ポリペプチド含有製剤
JPH06345665A (ja) 生理学的に活性なペプチドを含有する膣投与製剤
JP3181062B2 (ja) 下部消化管崩壊経口製剤
WO2024012589A1 (zh) 一种多肽组合物、药物、药物组合物及其应用
JP3009911B2 (ja) ペプチド又は蛋白の内服用新規製剤
TW202430205A (zh) 口服多肽組成物及其用途
JPH0585941A (ja) マトリツクス製剤
AU2013205707A1 (en) Solid oral dosage form containing an enhancer

Legal Events

Date Code Title Description
MA Patent expired